Company profile for Artiva Biotherapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors. Artiva Biotherapeutics was founded on the understanding that NK cells hold enormous therapeutic potential as cancer therapies and the dedication and expertise to overcome technological barriers in the scaling and manufacturing of these cells. At Artiv...
Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors. Artiva Biotherapeutics was founded on the understanding that NK cells hold enormous therapeutic potential as cancer therapies and the dedication and expertise to overcome technological barriers in the scaling and manufacturing of these cells. At Artiva, our mission is to deliver highly effective cell therapies that are also safe and immediately available and accessible to any cancer patient who stands to benefit.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
4747 Executive Drive #1150 San Diego, CA 92121
Telephone
Telephone
1.858.267.4467
Linkedin
Linkedin
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/12/3186050/0/en/Artiva-Biotherapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Recent-Business-Highlights.html

GLOBENEWSWIRE
12 Nov 2025

https://www.globenewswire.com/news-release/2025/11/12/3186104/0/en/Artiva-Biotherapeutics-Announces-Positive-Initial-Safety-and-Translational-Data-Supporting-Deep-B-Cell-Depletion-with-AlloNK-in-Autoimmune-Disease.html

GLOBENEWSWIRE
12 Nov 2025

https://www.globenewswire.com/news-release/2025/11/03/3179796/0/en/Artiva-Biotherapeutics-to-Host-Virtual-Event-Discussing-Initial-Safety-and-Translational-Data-in-up-to-32-Patients-with-Autoimmune-Disease-Treated-with-AlloNK.html

GLOBENEWSWIRE
03 Nov 2025

https://www.globenewswire.com/news-release/2025/10/30/3177964/0/en/Artiva-Biotherapeutics-to-Participate-in-Upcoming-Investor-Conferences-in-November.html

GLOBENEWSWIRE
30 Oct 2025

https://www.globenewswire.com/news-release/2025/10/16/3168298/0/en/Artiva-Biotherapeutics-Announces-Refractory-Rheumatoid-Arthritis-as-Lead-Indication-Upcoming-Data-Releases-and-Corporate-Update.html

GLOBENEWSWIRE
16 Oct 2025

https://www.globenewswire.com/news-release/2025/08/25/3138839/0/en/Artiva-Biotherapeutics-to-Participate-in-the-Cantor-Global-Healthcare-Conference-2025.html

GLOBENEWSWIRE
25 Aug 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty